Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2013. The report details a specific share repurchase transaction executed on July 22, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,000,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,695 pence per share; lowest price paid was 1,686 pence per share.
- Treasury Holdings (Settled): 502,849,512 shares (9.29% of total issued share capital).
- Treasury Holdings (Including Unsettled): 503,849,512 shares (10.26% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,908,781,520 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,000,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.26% when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (502,849,512 settled) against the company's latest capitalization table.
- Confirm the calculation of voting rights (10.26%) including unsettled shares for disclosure threshold assessments.
- Review the price range (1,686 to 1,695 pence) to assess the cost basis of the repurchase relative to market prices on July 22, 2013.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.